Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/15/2003CA2789407A1 Inhibitor oligonucleotides and their use for specific repression of a gene
05/15/2003CA2505129A1 Pharmaceutical compositions of marine sponge microciona prolifera
05/15/2003CA2474196A1 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
05/15/2003CA2472097A1 Antisense modulation of purinoreceptor p2x3
05/15/2003CA2469818A1 Anticancer compositions
05/15/2003CA2467955A1 Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions
05/15/2003CA2466880A1 Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
05/15/2003CA2466516A1 Targeting the reverse mode of the na+/ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
05/15/2003CA2466492A1 Antigen arrays presenting il-5, il-13 or eotaxin for treatment of allergic eosinophilic diseases
05/15/2003CA2466443A1 Selective treatment of il-13 expressing tumors
05/15/2003CA2466391A1 Polyamide modulators of cox2 transcription
05/15/2003CA2466334A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
05/15/2003CA2466333A1 Method of proliferation in neurogenic regions
05/15/2003CA2466303A1 Selective targeting of apoptotic cells
05/15/2003CA2466232A1 Systems for delivery and release of angiotensin-(1-7)
05/15/2003CA2466138A1 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003CA2466106A1 Methods of treating endometreosis
05/15/2003CA2466083A1 Compositions for the treatment of infectious diseases
05/15/2003CA2465981A1 Antigen arrays comprising rankl for treatment of bone disease
05/15/2003CA2465953A1 Novel isoforms of vascular endothelial cell growth inhibitor
05/15/2003CA2465945A1 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003CA2465886A1 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
05/15/2003CA2465499A1 Compositions and methods for treating osteoporosis
05/15/2003CA2465361A1 Treatment of human cancer with adenoviral vector expressing tnf-.alpha.
05/15/2003CA2465239A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/15/2003CA2464765A1 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003CA2464736A1 Beta-secretase inhibitors and methods of use
05/15/2003CA2464626A1 Method for the in vitro synthesis of short double stranded rnas
05/15/2003CA2464615A1 Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides
05/15/2003CA2464614A1 Pharmaceutical composition comprising factor vii polypeptides and pai-1 polypeptides
05/15/2003CA2464531A1 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
05/15/2003CA2464529A1 Method of treating estrogen responsive breast cancer
05/15/2003CA2464470A1 Novel epidermal growth factor protein and gene, and methods of use therefor
05/15/2003CA2463855A1 Weed controller metabolism proteins, genes thereof and use of the same
05/15/2003CA2463745A1 Peptide decoys for the preparation of medicaments that are intended for the prevention or treatment of autoimmune pathologies or problems linked to the appearance of antibodies directed against exogenous proteins
05/15/2003CA2463325A1 Novel proteins and nucleic acids encoding same
05/15/2003CA2462502A1 Improved use of antitumoral compound in cancer therapy
05/15/2003CA2462462A1 Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
05/15/2003CA2460653A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/14/2003EP1310571A2 A Method of detecting and/or identifying adeno-associated virus (AVV) sequences and isolating novel sequences identified thereby
05/14/2003EP1310559A1 Process for the production of alpha interferon of therapeutical degree
05/14/2003EP1310558A2 Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
05/14/2003EP1310555A2 Oligonucleotide modulation of protein kinase C
05/14/2003EP1310554A1 Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same
05/14/2003EP1310552A2 Posh nucleic acids, polypeptides and related methods
05/14/2003EP1310507A2 Novel peptide nucleic acids
05/14/2003EP1310482A1 Prodrugs of excitatory amino acids
05/14/2003EP1310261A1 Use of the extract of Vigna aconitifolia in a cosmetic and/or dermopharmaceutical composition
05/14/2003EP1310260A1 Mixed chimerism and tolerance
05/14/2003EP1309726A2 Rna sequence-specific mediators of rna interference
05/14/2003EP1309725A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human fetal liver
05/14/2003EP1309724A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human breast and bt 474 cells
05/14/2003EP1309723A2 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human breast and hbl 100 cells
05/14/2003EP1309716A2 A method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
05/14/2003EP1309705A2 Multivalent target binding protein
05/14/2003EP1309704A2 Regulation of human membrane-type serine protease
05/14/2003EP1309703A2 Kallikrein gene
05/14/2003EP1309701A2 Myrosinase from brevicoryne brassicae
05/14/2003EP1309700A2 Human phosphodiesterases
05/14/2003EP1309699A2 Elongase genes and uses thereof
05/14/2003EP1309697A2 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
05/14/2003EP1309693A2 Anti-dual integrin antibodies, compositions, methods and uses
05/14/2003EP1309692A2 Anti-il-12 antibodies, compositions, methods and uses
05/14/2003EP1309691A2 Anti-tnf antibodies, compositions, methods and uses
05/14/2003EP1309689A2 Genes involved in immune related responses observed with asthma
05/14/2003EP1309687A2 Leucine-rich repeat-containing g-protein coupled receptor-8 molecules and uses thereof
05/14/2003EP1309686A2 Slgp protein and nucleic acid molecules and uses therefor
05/14/2003EP1309685A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
05/14/2003EP1309684A2 Polynucleotides and polypeptides encoded thereby
05/14/2003EP1309683A2 Proteins and nucleic acids encoding same
05/14/2003EP1309682A2 Tetraspan protein and uses thereof
05/14/2003EP1309676A2 Human epithin-like serine protease
05/14/2003EP1309627A1 Immunotherapy for chronic myelocytic leukemia
05/14/2003EP1309625A2 Therapeutic compounds for ovarian cancer
05/14/2003EP1309624A2 Hcn polypeptides and polynukleotides and their use in therapy
05/14/2003EP1309623A2 G protein-coupled receptors from human clone "26908" and uses thereof
05/14/2003EP1309622A2 Lat peptides and their use in assays for identifying immunosuppressants
05/14/2003EP1309620A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
05/14/2003EP1309618A2 Leucine-based motif and clostridial neurotoxins
05/14/2003EP1309616A1 Integrin binding motif containing peptides and methods of treating skeletal diseases
05/14/2003EP1309614A2 Novel secreted proteins and their uses
05/14/2003EP1309613A2 Pharmaceutical composition comprising an analgesic peptide
05/14/2003EP1309611A1 Anti-heparin peptides
05/14/2003EP1309610A2 Peptide and peptide mimetic derivatives with integrin inhibitor properties ii
05/14/2003EP1309609A2 Lactam compounds and their use as inhibitors of serine proteases and method
05/14/2003EP1309607A2 Method for producing peptide salts, their use, and pharmaceutical preparations containing these peptide salts
05/14/2003EP1309374A2 Methods and compositions for treating ige-related disease using nnt-1 inhibitors
05/14/2003EP1309373A2 Method and composition for altering a t cell mediated pathology
05/14/2003EP1309369A1 Electro-powder
05/14/2003EP1309355A1 Peptide and peptide mimetic conjugates with integrin-inhibitor properties
05/14/2003EP1309347A2 Method and composition for altering a b cell mediated pathology
05/14/2003EP1309346A2 Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
05/14/2003EP1309341A2 Prevention and treatment of alzheimer's disease
05/14/2003EP1309340A1 High mannose proteins and methods of making high mannose proteins
05/14/2003EP1309339A2 Stimulating neutrophil function to treat inflammatory bowel disease
05/14/2003EP1309338A1 Pharmaceutical composition comprising trkaig2 for use in the prevention and/or treatment of cancer
05/14/2003EP1309337A2 Use of gadd34 or pcna polypeptides in the treatment of cerebral ischaemic damage
05/14/2003EP1309336A1 Derivatives of laspartomycin and preparation and use thereof
05/14/2003EP1309334A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
05/14/2003EP1309312A2 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
1 ... 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 ... 3163